The FDA drug center’s new acting director Tracy Beth Høeg fits a pattern of risky, internal contradictions among agency ...
Nothing corrodes public trust in a regulatory agency faster than the sense that its senior officials are auditioning for ...
The chaos created by the freezing and termination of billions of dollars of research grants has left trans academics ...
Dyne Therapeutics plans to submit its next-gen Duchenne muscular dystrophy drug to the FDA after a successful trial.
An investigational GLP-1 pill from Structure Therapeutics led to substantial weight loss, but patients also had high rates of ...
If any ambiguity remained about the ultimate goal of the current administration’s public health policy, last week shattered ...
The ASH meeting included positive early results about a Terns drug for chronic myeloid leukemia and a Kura menin-blocker for ...
After two days of contentious discussion, federal vaccine advisers voted Friday in favor of a major change to childhood ...
Terns Pharmaceuticals reports its targeted leukemia drug maintained and even boosted molecular response rates in ...
And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter ...
Apparently, some vets are already using GLP-1s for diabetic cats. We are all a clinical trial or two away from “Ozempets” ...
From my colleague Elaine Chen: Wave Life Sciences said today that interim data show its investigational siRNA therapy cut ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results